GEN

Editas Early Data for CRISPR Therapy EDIT-101 Shows Efficacy “Signals” in Two Patients

Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, ...
Morningstar

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational ...

The first patient, who received GEB-101 in May 2025, has been discharged from the collaborating hospital with no observable adverse event. This trial marks the world's first clinical study of an in ...
Managingip.com

CRISPR interference decision, Center for Intellectual Property Understanding, Alibaba, Section 101, Northern District of California – the week in IP

The USPTO has ruled there is “no interference in fact” in the closely-watched dispute over CRISPR patents between the University of California and the Broad Institute, reports MIT Technology Review.
ksn.com

Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1

EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and ...
The Scientist

Beckman Coulter Life Sciences: CRISPR 101

CRISPR has increasingly gained popularity in its role with immunotherapy over the years. This short video introduces CRISPR as related to immunotherapy, as well as its capabilities now and into the ...